Replies to post #234483 on Biotech Values

[DewDiligence]

VYNE -31% on phase-2 failure in atopic dermatitis:

https://www.globenewswire.com/news-release/2022/08/10/2495777/0/en/VYNE-Therapeutics-Announces-Results-from-its-Phase-2a-Trial-of-FMX114-for-the-Treatment-of-Mild-to-Moderate-Atopic-Dermatitis.html

Yet another instance where a corporate name change (#msg-158051512) was a harbinger of trouble.